
|Articles|October 1, 2003
Topical Tx for Thin Skin
New York - With the results of two previous open trials supporting clinical use of tacrolimus (Protopic) and pimecrolimus (Elidel), current data affirms that the topical immunomodulators are the definitive treatment of choice for facial and intertriginous psoriasis, according to Mark Lebwohl, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















